Panlobular emphysema is a pattern of lung destruction in which the tiny air sacs spread uniformly throughout an entire lung unit, rather than clustering around small airways the way the more common smoking-related form does. It is most closely linked to alpha-1 antitrypsin deficiency, a genetic condition, and it tends to hit the lower portions of the lungs hardest. Because its damage is diffuse and evenly distributed, panlobular emphysema can be surprisingly difficult to spot on imaging and often behaves differently from other forms of emphysema when it comes to treatment response.
What Happens Inside the Lung
The lung is organized into small functional units. Within each unit, air flows through tiny branching passages and eventually reaches clusters of air sacs where oxygen and carbon dioxide are exchanged. In panlobular emphysema, the walls of these air sacs break down more or less uniformly across the entire unit, from center to periphery.1Update in Respiratory Diseases. Emphysema That uniform involvement is what sets it apart from centrilobular emphysema, where destruction begins in the center of the unit and fans outward only as the disease worsens. The result is a lung that looks almost featureless on close inspection: the normal delicate architecture of tiny pockets and thin walls gives way to larger, emptier spaces with fewer surfaces for gas exchange.
This distinction matters because the two patterns have different causes, different locations within the chest, and different implications for treatment. Centrilobular emphysema is strongly linked to cigarette smoking and favors the upper portions of the lungs. Panlobular emphysema is more diffuse within lobes and lungs, with a mild preference for the lower lobes.2BMJ Journals. Centrilobular emphysema and panlobular emphysema: two different diseases That lower-lobe predominance is one of the clinical clues that can point a physician toward the panlobular pattern and, by extension, toward an underlying genetic cause.
The Alpha-1 Antitrypsin Connection
The most well-established cause of panlobular emphysema is alpha-1 antitrypsin deficiency (AATD). Alpha-1 antitrypsin is a protein produced mainly by the liver that travels through the bloodstream to the lungs, where its job is to keep a destructive enzyme called neutrophil elastase in check. Neutrophil elastase is released by white blood cells as part of the normal immune response, and it is extremely good at breaking down proteins in its path. In a healthy person, alpha-1 antitrypsin neutralizes that enzyme before it can chew through lung tissue. In someone with AATD, the protective protein is either absent or produced in a misfolded form that gets stuck inside liver cells rather than reaching the lungs.3PubMed. Alpha(1)-antitrypsin deficiency, liver disease and emphysema
Without adequate protection, neutrophil elastase slowly degrades the elastic fibers that give the air sacs their springiness. The lung loses its ability to recoil during exhalation, air gets trapped, and the air sacs progressively enlarge and merge. This imbalance between the destructive enzyme and its missing inhibitor is sometimes called the protease-antiprotease imbalance, and it is the central mechanism driving panlobular emphysema in AATD.4PubMed. Neutrophil elastase-mediated lung disease Because AATD is inherited, panlobular emphysema often appears at a younger age than smoking-related disease, particularly in people who also smoke. Smoking accelerates the damage dramatically because it recruits even more neutrophils into the lungs while simultaneously inactivating whatever small amount of alpha-1 antitrypsin might still be circulating.5Elsevier / Respir Med. Small airways disease in patients with alpha-1 antitrypsin deficiency
AATD also affects the liver. The misfolded protein that cannot be secreted forms clumps inside liver cells, and over time these can cause liver inflammation, cirrhosis, and even liver cancer.6PubMed. Alpha(1)-antitrypsin deficiency, liver disease and emphysema So someone with severe AATD may face simultaneous threats to both organs, a dual burden that is easy to overlook if clinicians focus only on the lungs.
Non-Genetic Causes
Although AATD gets the most attention, panlobular emphysema can also develop in people with normal alpha-1 antitrypsin levels. One striking example is intravenous methylphenidate (Ritalin) abuse. When tablets intended for oral use are crushed, dissolved, and injected, the filler materials in the tablets, particularly talc, lodge in the small blood vessels of the lungs. A study of seven patients who injected methylphenidate found severe panlobular emphysema concentrated in the lower lungs, accompanied by microscopic talc deposits. The pattern closely resembled AATD-related disease both on imaging and under the microscope, yet these patients had no genetic deficiency.7PubMed. Panlobular emphysema in young intravenous Ritalin abusers
A larger imaging review of 21 intravenous methylphenidate users confirmed the same picture: emphysema was worst at the lung bases, was symmetric, and progressed over a span of two to seven years on serial chest imaging.8PubMed. Panlobular pulmonary emphysema caused by i.v. injection of methylphenidate (Ritalin): findings on chest radiographs and CT scans Exactly how the injected talc triggers the same uniform pattern of air sac destruction seen in AATD is not fully understood. One theory is that talc particles provoke a sustained inflammatory response that floods the lung with the same destructive enzymes normally kept in check by alpha-1 antitrypsin, essentially recreating the protease-antiprotease imbalance through a different route. The pattern of lower-lobe predominance in these patients is a useful diagnostic clue: a young person with basal emphysema and no family history of AATD should be asked about IV drug use.
How It Shows Up on Imaging
Panlobular emphysema is notoriously harder to see on CT scans than centrilobular emphysema, precisely because the damage is so uniform. Centrilobular emphysema produces small, well-defined holes near the centers of lung units that stand out clearly against the surrounding normal tissue. In panlobular emphysema, the entire region is affected at roughly the same intensity, so there is less contrast between destroyed and preserved tissue. On high-resolution CT, it typically appears as either a generalized decrease in lung density across an entire lobe or as vaguely defined areas of low density without the discrete “holes” that characterize the centrilobular pattern.9PubMed Central. Imaging of pulmonary emphysema: a pictorial review
This subtlety means panlobular emphysema can be underdiagnosed, especially in its earlier stages. Quantitative CT techniques that measure the percentage of lung volume below a certain density threshold can help. These software tools flag regions where the tissue has become abnormally thin and airy, even when the human eye has trouble distinguishing them from normal variation. Research into refining these measurements is ongoing, and newer algorithms may improve detection, but the fundamental challenge remains: uniform damage is inherently less conspicuous than focal damage.10Chronic Obstr Pulm Dis. Panlobular Emphysema: Enhancing Visibility with Quantitative Computed Tomography
One practical takeaway: if a CT report describes lower-lobe-predominant emphysema without the typical upper-lobe centrilobular pattern, and the patient is relatively young or has limited smoking history, that finding should prompt testing for AATD and a careful look at drug use history. The imaging pattern itself is a signal that the underlying disease may need a very different management approach.
Differences in Lung Function and Disease Severity
You might expect that two patterns of the same fundamental process, destruction of air sacs, would affect lung function in similar ways. They do share some overlap, but there are measurable differences. A study comparing patients with panlobular versus centrilobular emphysema found that panlobular emphysema was more common in people with severe and very severe airflow obstruction. It was also present in about 38% of those with milder disease, so it is not exclusively a late-stage finding.11PubMed Central. Physiologic and Quantitative Computed Tomography Differences Between Centrilobular and Panlobular Emphysema in COPD
One interesting finding from that study was that the relationship between airway wall thickness and airflow limitation was weaker in panlobular emphysema than in the centrilobular pattern. In centrilobular disease, thickened small airways contribute substantially to obstruction, so airway wall measurements on CT correlate fairly tightly with breathing-test results. In panlobular emphysema, the obstruction comes more from the loss of lung elastic recoil and air trapping than from airway narrowing, so the airway walls may look relatively normal even when the patient is severely limited.12PubMed Central. Physiologic and Quantitative Computed Tomography Differences Between Centrilobular and Panlobular Emphysema in COPD For clinicians, this means that standard markers of airway disease can underestimate how much trouble a panlobular emphysema patient is in.
Another pattern worth noting: panlobular emphysema was negatively associated with pack-years of smoking in that same study. In other words, the more someone had smoked, the less likely panlobular emphysema was to be the dominant pattern. This reinforces the idea that panlobular emphysema is driven more by genetic vulnerability or other non-smoking exposures, while heavy smoking tends to produce the centrilobular pattern.
Airway Disease and Bronchiectasis
Panlobular emphysema in AATD does not exist in isolation. The same proteolytic damage that destroys air sacs also affects the small and medium-sized airways. In patients with severely deficient alpha-1 antitrypsin, areas of panlobular emphysema often show airway dilation consistent with bronchiectasis, a condition where the walls of the bronchial tubes become permanently stretched and scarred.13PubMed Central. Airway disease in alpha-1 antitrypsin deficiency Bronchiectasis brings its own problems: chronic cough, frequent respiratory infections, and mucus production that can further worsen airflow.
This overlap means that some AATD patients experience a combination of obstructive emphysema and recurrent infections that mimics other chronic lung conditions. It also means treatment plans often need to address both the emphysema component and the airway disease component separately, for example combining bronchodilators with airway clearance techniques and sometimes antibiotics for flare-ups.
Treatment for AATD-Related Panlobular Emphysema
The standard treatment for COPD applies to panlobular emphysema regardless of cause. Inhaled bronchodilators remain the foundation because they improve symptoms, quality of life, and reduce flare-ups.14Journal of Allergy and Clinical Immunology. Outpatient treatment of chronic obstructive pulmonary disease: Comparisons with asthma Pulmonary rehabilitation, a structured program of exercise and education, also helps by improving exercise tolerance and reducing hospitalizations.15Journal of Allergy and Clinical Immunology. Outpatient treatment of chronic obstructive pulmonary disease: Comparisons with asthma Smoking cessation, if relevant, is critical.
For patients whose panlobular emphysema is specifically driven by AATD, there is an additional option: augmentation therapy. This involves regular intravenous infusions of purified alpha-1 antitrypsin protein derived from donated human plasma. The goal is to restore the protective protein to levels that can shield the lungs from ongoing elastic fiber destruction. Evidence from the RAPID trial and its extension showed that augmentation therapy slowed the loss of lung density over four years. Patients who started treatment immediately lost lung density more slowly than those who initially received a placebo, and when the placebo group crossed over to active treatment, their rate of density loss improved as well.16The Lancet Respiratory Medicine. Efficacy and safety of long-term alpha-1 proteinase inhibitor therapy on the progression of emphysema in severe alpha-1 antitrypsin deficiency (RAPID-OLE)
Expert guidelines recommend augmentation therapy particularly for AATD patients with moderate airflow obstruction, where the benefit appears best documented. The therapy is also associated with lower levels of elastin breakdown products in the blood, providing a biochemical signal that the destructive process is being slowed.17Chronic Obstr Pulm Dis. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult Augmentation therapy does not reverse existing damage, so earlier diagnosis and treatment initiation tend to preserve more lung function over time.
Why Lung Volume Reduction Surgery Often Fails
Lung volume reduction surgery, which removes the most damaged portions of the lung to allow healthier tissue to expand and function better, has helped many patients with upper-lobe-predominant centrilobular emphysema. The logic is straightforward: cut away the worst-performing tissue, and the remaining lung can inflate more effectively and the diaphragm works in a better mechanical position. But panlobular emphysema tends to distribute its damage evenly, which means there is no “worst” zone to remove. Cutting out one region just leaves the patient with less overall lung, and the remaining tissue is equally diseased.
A study evaluating outcomes of lung volume reduction surgery found that all patients with lower-lobe-predominant or whole-lung panlobular emphysema rated their results as “worse” after the procedure.18PubMed. Subjective symptoms and prognosis after lung volume reduction surgery in patients with severe pulmonary emphysema This is a sobering finding and a practical one: if you or someone you know has been told they have panlobular emphysema and is being considered for lung volume reduction surgery, that pattern of disease is a strong reason to approach the option with caution. Lung transplantation remains an option for severe cases in patients who are otherwise good surgical candidates, and it avoids the problem of diffuse disease by replacing the lungs entirely.
Tracking Progression With Biomarkers
One challenge in managing panlobular emphysema is measuring whether it is getting worse and whether treatment is working. Lung function tests capture overall airflow, but they are blunt instruments that do not directly measure tissue destruction. CT density measurements are more sensitive but require radiation exposure and are impractical for frequent monitoring. Researchers have been investigating blood and urine biomarkers that could fill this gap.
The most promising candidates are desmosine and isodesmosine, two amino acids found only in mature elastic fibers. When elastic fibers in the lung are broken down, desmosine and isodesmosine are released into the bloodstream and eventually excreted in urine. Their levels may reflect ongoing lung tissue destruction in real time.19PubMed Central. Desmosine: The Rationale for Its Use as a Biomarker of Therapeutic Efficacy in the Treatment of Pulmonary Emphysema Because these molecules come specifically from elastin and nowhere else in the body, they offer a direct window into the process that drives panlobular emphysema.
Data from the RAPID augmentation therapy trials confirmed the clinical usefulness of this approach. Patients receiving alpha-1 antitrypsin infusions had significantly lower desmosine and isodesmosine levels compared to baseline at every time point measured over four years. The reduction in these biomarkers correlated with slower loss of lung density on CT, linking a simple blood measurement to an anatomical outcome.20PubMed Central. The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials Longitudinal tracking of these markers may eventually allow clinicians to adjust treatment intensity based on how much destruction is still occurring, rather than waiting for breathing tests to decline.21PubMed. Long-term variability of desmosine/isodesmosine as biomarker in alpha-1-antritrypsin deficiency-related COPD
Aging and the Panlobular Pattern
There is one more context in which the term “panlobular emphysema” comes up, and it is worth mentioning because it can cause confusion. Normal aging produces changes in the lung that superficially resemble panlobular emphysema. As people get older, the air spaces in the lung gradually enlarge and the elastic tissue becomes less springy. On imaging, this can look like mild, diffuse emphysema. However, aging-related air space enlargement involves stretching and dilation of the existing structures rather than outright destruction of the walls between air sacs.22American Review of Respiratory Disease. A Comparative Study of the Mechanical Properties in Aging Alveolar Wall
The distinction has practical consequences. An older adult whose CT shows mild, diffuse low attenuation in the lower lungs does not necessarily have panlobular emphysema requiring workup for AATD. The difference can sometimes be teased out by measuring how the lung’s elastic properties change, since true emphysema involves wall destruction that alters mechanics differently from simple stretching. Still, in borderline cases, the overlap can make diagnosis tricky, and clinicians sometimes need to combine imaging, lung function testing, and blood tests to tell the two apart.